Table 3.
Comparison of mutated genes at baseline and disease progression in pooled MCL samples
| Gene | MF, % | Change, % | Pr(MFprogression>MFbaseline|data) | |
|---|---|---|---|---|
| Baseline | Disease progression | |||
| TP53 | 26.8 | 43.0 | 16.2 | 0.998 |
| ATM | 43.5 | 57.6 | 14.1 | 0.990 |
| KMT2A | 8.9 | 21.4 | 12.5 | 0.878 |
| MAP3K14 | 2.4 | 14.2 | 11.8 | 0.994 |
| BTK | 5.5 | 17.1 | 11.6 | 0.928 |
| TRAF2 | 4.5 | 15.7 | 11.2 | 0.996 |
| CHD2 | 4.0 | 14.1 | 10.1 | 0.973 |
| TLR2 | 4.3 | 14.3 | 10.0 | 0.964 |
| ARID2 | 6.8 | 16.3 | 9.5 | 0.867 |
| RIMS2 | 8.2 | 17.3 | 9.1 | 0.876 |
| NOTCH2 | 5.8 | 14.3 | 8.5 | 0.971 |
| TET2 | 5.6 | 14.1 | 8.5 | 0.942 |
| SPEN | 5.9 | 14.2 | 8.3 | 0.879 |
| NSD2 | 15.0 | 22.8 | 7.8 | 0.931 |
| CARD11 | 8.5 | 16.3 | 7.8 | 0.893 |
| CCND1 | 20.2 | 27.7 | 7.5 | 0.923 |
| SP140 | 8.4 | 14.3 | 5.9 | 0.799 |
| CDKN2A | 23.9 | 29.5 | 5.6 | 0.784 |
| S1PR1 | 8.6 | 13.9 | 5.3 | 0.757 |
MCL, mantle cell lymphoma; MF, mutation frequency; Pr, Bayesian probability.